Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement

Executive Summary

With the first few cell and gene therapies launched in the US, the challenge of pricing and reimbursement – and the opportunity to set the standards in this area – was a repeated theme at the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa.

You may also be interested in...



Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies

The European Commission has officially approved Luxturna, Novartis/Spark Therapeutics’ transformative gene therapy. The Swiss firm tells Scrip how the lessons it expects to learn from launching its first gene therapy will inform its future strategy in this new field.

Another CAR-T First: Yescarta Wins Lymphoma Funding In England

Gilead has agreed a confidential deal with NHS England under which its pioneering CAR-T therapy Yescarta will be provided to adult lymphoma patients under the Cancer Drugs Fund. The funding decision gives Yescarta an edge in the lymphoma market over Kymriah, the other EU-authorized CAR-T treatment.

Kymriah: England Becomes First In Europe To Say Yes To CAR-T

A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123961

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel